Business, energy, technology, markets and global industry news from Business News Today

oncology trials

PharmaDeviceNews oncology trials
Representative image: A clinician reviews spinal imaging as Zetagen Therapeutics’ ZetaMet Phase 2a data highlights investigational progress in treating metastatic breast cancer patients with lytic bone lesions.
Pharma & Biotech

Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?

Find out how Zetagen’s ZetaMet Phase 2a data may reshape treatment of metastatic breast cancer bone lesions.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More
Representative image of oncology researchers studying tumor biology in a modern laboratory, reflecting Exelixis’ CABINET trial data on CABOMETYX and its potential role in advanced neuroendocrine tumor treatment.
Pharma & Biotech

Can Exelixis defend its oncology franchise with deeper CABINET evidence?

Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.

Read More
Representative image of an oncologist and clinical care team reviewing AI-powered cancer trial data, reflecting Massive Bio’s Reticulum Nexus push to improve oncology trial matching, biomarker reassessment and patient access after its ASCO 2026 product suite announcement.
Pharma & Biotech

How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials

Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!

Read More
Representative image of oncology researchers reviewing colorectal cancer imaging and clinical trial data, reflecting how the KLEOS adaptive trial platform could support faster evaluation of new colorectal cancer therapies.
Pharma & Biotech

Can KLEOS change how colorectal cancer trials are run for patients with limited treatment options?

CRC trials need faster evidence. KLEOS could test more therapies under one platform. Read why the model matters.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More
Representative image of AI-powered digital pathology and oncology biomarker analysis, illustrating how Daiichi Sankyo and Waiv’s ADC collaboration could support smarter patient selection in precision cancer drug development.
Pharma & Biotech

Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials

ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.

Read More
Pharma & Biotech

Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight

FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.

Read More
Pharma & Biotech

What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy

Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.

Read More
Pharma & Biotech

AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy

Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.

Read More